The Effects of Administrated Dexamethasone on Neurologic Assessment in Neuro-oncology Scale in Patients with Intracranial Tumors
DOI:
https://doi.org/10.3889/oamjms.2021.6314Keywords:
Dexamethasone, Neurologic assessment in neuro-oncology score, Intracranial tumorAbstract
BACKGROUND: In intracranial tumors, glucocorticoids are the main therapy to treat peritumoral edema. Neurologic Assessment in Neuro-Oncology (NANO) score is an instrument that can assess neurological function objectively and practically in patients with intracranial tumors.
AIM: This study aims to determine the effect of dexamethasone administration on the NANO score of intracranial tumor patients.
METHODS: This study was a pre-experimental study with a pre and post-test design at the H. Adam Malik General Hospital in Medan from March to September 2020. The study population was intracranial tumor patients. The research subject were 37 subjects taken consecutively. Treated with dexamethasone injection, then examined the NANO score before and after receiving dexamethasone injection on days 1, 2, and 3. Statistical analysis with Friedman test.
RESULTS: Based on the demographic characteristics of the research subjects, the mean age was 53.29 ± 8.5 years. Most of the research subjects were male (54.1%) while female (45.9%). Most types of intracranial tumors were secondary tumors (59.5%) while primary tumors (40.5%). The significant effect of dexamethasone on NANO score in patients with intracranial tumors (p < 0.001).
CONCLUSION: There is an effect of dexamethasone on the NANO score of patients with intracranial tumors.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
American Association of Neurological Surgerons (AANS). Brain Tumors. Available from: https://www.aans.org/2012. [Last accessed on 2021 May 14].
Satria A. Two-year Life Expectancy for Patients with Low Grade and High Grade Glioma Receiving Radiation Therapy. Scientific Papers. Semarang: Diponegoro University; 2011.
National Cancer Management Committee (KPKN). Brain Tumor. Jakarta: Ministry of Health of the Republic of Indonesia. National Cancer Management Committee; 2017.
Fan Z, Sehm T, Rauh M, Buchfelder M, Eyupoglu IY, Savaskan NE. Dexamethasone alleviates tumor-associated brain damage and angiogenesis. PLoS One. 2014;9(4):e93264. http://doi.org/10.1371/journal.pone.0093264 PMid:24714627 DOI: https://doi.org/10.1371/journal.pone.0093264
Kaal EA, Vecht CJ. The management of brain edema in brain tumors. Curr Opin Oncol 2004;16(6):593-600. http://doi.org/10.1097/01.cco.0000142076.52721.b3 PMid:15627023 DOI: https://doi.org/10.1097/01.cco.0000142076.52721.b3
Drappatz J, Schiff D, Kesari S, Norden AD, Wen PY. Medical management of brain tumor patients. Neurol Clin. 2007;25(4):1035-71. http://doi.org/10.1016/j.ncl.2007.07.015 PMid:17964025 DOI: https://doi.org/10.1016/j.ncl.2007.07.015
Husna U, Dalhar M. Pathophysiology and management of cerebral edema. MNJ. 2017;3(2):94-107. DOI: https://doi.org/10.21776/ub.mnj.2017.003.02.7
Setiawan A, Pudjonarko D, Tasworo D. The effect of dexamethasone administration on plasma D Dimer levels in brain tumor patients. Med Hosp. 2015;3(1):25-31.
Palombi L, Marchetti P, Salvati M, Osti MF, Frati L, Frati A. Interventions to reduce neurological symptoms in patients with GBM receiving radiotherapy: From theory to clinical practice. Anticancer Res 2018;38:2423-7. http://doi.org/10.21873/anticanres.12494 PMid:29599372 DOI: https://doi.org/10.21873/anticanres.12494
Kural C, Atac GK, Tehli O, Solmaz I, Temiz C, Hodaj I, Izci Y. The evaluation of the effects of steroid treatment on the tumor and peritumoral edema by DWI and MR spectroscopy in brain tumors. Neurol Neurochir Pol. 2018;52(4):495-504. http://doi.org/10.1016/j.pjnns.2018.03.002 PMid:29588064 DOI: https://doi.org/10.1016/j.pjnns.2018.03.002
Neuro-Oncology Study Group. Neurooncology Textbook. 1st ed. Jakarta: Association of Indonesian Neuroscientists (PERDOSSI); 2019. p. 1-209.
Mariska, Nasution IK, Fithrie A. Association between ages and glucocorticoid-induced diabetes mellitus incidence in intracranial tumor patients. Int J Res Sci Manag 2020;7(7):17-22. DOI: https://doi.org/10.29121/ijrsm.v7.i7.2020.3
Mckinney PA. Brain tumours: Incidence, survival, and aetiology. J Neurol Neurosurg Psychiatry. 2004;75(2):12-7. http://doi.org/10.1136/jnnp.2004.040741 PMid:15146034 DOI: https://doi.org/10.1136/jnnp.2004.040741
Chitra I, Andriani R. Secondary brain tumors (Metastases). In: Aninditha T, Andriani R, Malueka RG, editors. Neurooncology Textbook. Jakarta: Neuro-Oncology Study Group, Indonesian Association of Neuroscientists Indonesian Medical Publishers; 2019. p. 199-213.
Schultz H, Rasmussen BK, Kristensen PL, Jensen AK, Bjergaard UP. Early incidence of glucocorticoid-induce diabetes in patients with brain tumors: A retrospective study of the first day of treatment. Neurooncol Pract. 2017;5(3):170-5. http://doi.org/10.1093/nop/npx027 PMid:31385948 DOI: https://doi.org/10.1093/nop/npx027
Nayak L, DeAngelis LM, Brandes AA, Peereboom DM, Galanis E, Lin NU, et al. The neurologic assessment in neuro oncology (NANO) scale: A tool to assess neurologic function for integration into the response assessment in neuro oncology (RANO) criteria. Neuro Oncol. 2017;19(5):625-35. http://doi.org/10.1093/neuonc/nox029 PMid:28453751 DOI: https://doi.org/10.1093/neuonc/nox029
Ung TH, Ney DE, Damek D, Rusthoven CG, Youssef AS, Lillehei KO, et al. The neurologic assessment in neuro oncology (NANO) scale as an assessment tool for survival in patients with primary glioblastoma. Neurosurgery 2018;84(3):687-95. http://doi.org/10.1093/neuros/nyy098 PMid:29618103 DOI: https://doi.org/10.1093/neuros/nyy098
Lee J, Park SH, Kim YZ. Prognostic evaluation of neurological assessment of the neuro oncology scale in glioblastoma patients. Brain Tumour Res Treatment. 2018;6(1):22-30. http://doi.org/10.14791/btrt.2018.6.e1 PMid:29644808 DOI: https://doi.org/10.14791/btrt.2018.6.e1
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2021 Muhamad Ibnu Sina, Cut Aria Arina, Irina Kemala Nasution (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
